Nav: Home

23andMe launches Genotyping Services for Research grant program

October 19, 2016

VANCOUVER, British Columbia - October 19, 2016 - 23andMe, Inc. today announced a grant program as part of its Genotyping Services for Research platform. The program aims to accelerate research studies and elicit proposals in which the 23andMe experience is likely to help facilitate participant recruitment and enhance engagement.

Proposals will be selected based on scientific significance, approach, feasibility, investigator expertise, innovativeness of the project and inclusion of the evaluation of the impact of return of genetic information on participant engagement. Educational institutions, universities and research centers performing genomics research in the United States are eligible.

Two proposals will be selected from among the program submissions; each will receive 200 23andMe DNA Collection kits for their prospective genotyping study. Beginning today, interested researchers can apply to the grant program at the following http://researchers.23andme.org/grant-program.

"At 23andMe our model is to treat research participants as true partners," said Ruby Gadelrab, 23andMe vice president of commercial marketing. "We find that study participants are much more engaged when they have the opportunity to learn about their personal genetic information, and this makes recruitment for research studies much easier."

The announcement of the grant program is part of a major company presence at the American Society of Human Genetics (ASHG) Annual Meeting, the world's largest gathering of human genetics researchers, this week in Vancouver. The company is presenting insights on the landmark population health study its powering in collaboration with Nevada-based health system Renown Health and the Desert Research Institute (DRI), which recruited more than 10,000 study volunteers in less than 48 hours. The study's principal investigator, Joe Grzymski, Ph.D., from DRI will be sharing information on the study and insights gleaned in the recruiting process.

The presentation will headline 23andMe's educational seminar, New Models in Genotyping: Incentivizing Recruitment, Engaging Participants and Accelerating Research Results. The seminar takes place Thursday, Oct. 20 from 1:00-2:30 p.m. in Ballroom B, East Building, Vancouver Convention Centre. Following is a full list of seminar topics:
  • How the consumerization of genomics benefits research
    Joyce Tung, Ph.D., VP of research, 23andMe
  • An integrated community health pilot study using 23andMe Genotyping Services for Research: how to rapidly recruit 10,000 participants.
    Joe Grzymski, Ph.D., Senior Director, Applied Innovation Center; Associate Research Professor, Computational Biology and Microbiology - Desert Research Institute
  • Studying impulsivity, alcoholism and loneliness using in person and internet-based phenotyping
    Abraham Palmer, Ph.D., Professor & Vice Chair for Basic Research, Department of Psychiatry - University of California San Diego
  • Studying multiple sclerosis patients at home using genotyping, MR imaging and phenotypic data collection from the myMS app
    Daniel Pelletier, Ph.D., Vice Chair of Research, Department of Neurology; Professor of Neurology and Radiology; Chief, Neuro-Immunology Division and USC Multiple Sclerosis Center; Director, Advanced Imaging in Multiple Sclerosis (AIMS) Laboratory; Keck School of Medicine -- USC
  • Reimagining genetic studies: Genotyping Services for Research
    Robert Borkowski, Ph.D., product manager, 23andMe
In addition, Richard Scheller, Ph.D., 23andMe chief science officer and head of therapeutics, is speaking today, Wednesday, Oct. 19, on the topic From GWAS and Mendelian Genes to Therapeutic Drug Targets.

23andMe scientists also have a number of scheduled platform and poster presentations on topics ranging from nail biting to body mass index (BMI).

Presentation: 23andMe posters (on display throughout conference): There are also a number of presentations and posters by 23andMe collaborators.

Platform presentations: Posters:
-end-
About 23andMe

23andMe, Inc. is the leading personal genetics company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe has more than one million customers worldwide, with over 80 percent consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at http://www.23andMe.com.

23andMe, Inc.

Related Multiple Sclerosis Articles:

New biomarkers of multiple sclerosis pathogenesis
Multiple sclerosis (MS) is a chronic debilitating inflammatory disease targeting the brain.
Using telemedicine to treat multiple sclerosis
Multiple sclerosis (MS) clinicians face continued challenges in optimizing neurological care, especially for people with advanced MS living in medically underserved communities.
Improving symptom tracking in multiple sclerosis
With a recent two-year, $833,000 grant from the US Department of Defense, kinesiology professor Richard van Emmerik and colleagues at the University of Massachusetts Amherst hope to eventually help an estimated 1 million people worldwide living with progressive multiple sclerosis by creating an improved diagnostic test for this form of the disease, which is characterized by a steady decrease in nervous system function.
An antibody-based drug for multiple sclerosis
Inserm Unit U919, directed by Professor Denis Vivien has developed an antibody with potential therapeutic effects against multiple sclerosis.
Four new risk genes associated with multiple sclerosis discovered
Scientists of the Technical University of Munich and the Max Planck Institute of Psychiatry have identified four new risk genes that are altered in German patients with multiple sclerosis.
PET detects neuroinflammation in multiple sclerosis
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular imaging is bringing researchers closer to identifying them, while providing a means of evaluating next-generation therapies for MS, say researchers introducing a study at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
Scientists find genetic cause of multiple sclerosis
Researchers have discovered a rare genetic mutation that makes it probable that a person will develop multiple sclerosis (MS).
ANKRD55: A new gene involved in Multiple Sclerosis is discovered
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55.
Children with and without multiple sclerosis have differences in gut bacteria
In a recent study, children with multiple sclerosis had differences in the abundance of specific gut bacteria than children without the disease.
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.

Related Multiple Sclerosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...